ADX-077

ADX-077 is an investigational small interfering RNA (siRNA) therapeutic being developed by ADARx Pharmaceuticals for the treatment of obesity and metabolic diseases. The drug is designed to leverage ADARx's proprietary RNA delivery technology to target and silence specific mRNA transcripts involved in metabolic regulation. While the specific molecular target of ADX-077 has not been publicly disclosed, the program is part of a broader pipeline of siRNA candidates aimed at addressing unmet needs in genetic, cardiometabolic, and central nervous system diseases. ADX-077 is currently in the early stages of development, following the company's strategy of utilizing its B-SIGHT and other proprietary platforms for highly specific and potent RNA interference.